临床IA期肺癌的长期结果:肺叶切除与亚肺叶切除的比较
基于美国外科医师学会国家癌症数据库2007至2012年增强数据,纳入1687例临床IA期非小细胞肺癌患者(肺叶切除1354例、亚肺叶切除333例),倾向性匹配后325对。两组5年总生存无显著差异(61.8% vs 55.6%,p=0.561),亚肺叶切除组复发风险增加39%(HR 1.39,95%CI 1.04–1.87),且淋巴结清扫数目更少、评估不充分。
要点
- 亚肺叶切除组5年总生存与肺叶切除组无显著差异(61.8% vs 55.6%,p=0.561)。
- 亚肺叶切除组NSCLC复发风险增加39%(HR 1.39,95%CI 1.04–1.87)。
- 亚肺叶切除组淋巴结数目中位数低于肺叶切除组(1枚[0,4] vs 7枚[3,10],p<0.001),多数淋巴结评估不充分。
核心结论
- 在代表IA期NSCLC真实结局的增强国家数据集中,亚肺叶切除与癌症复发风险增加39%相关。
- 接受亚肺叶切除的大多数患者淋巴结评估不充分。
- 在将现有比较这两种治疗的临床试验结果外推至临床使用时,必须考虑这些真实世界结果。
研究设计与样本
- 美国外科医师学会开展国家癌症数据库专项研究,自2007年至2012年重新摘录记录,补充术前合并症与癌症复发的增强信息。
- 纳入接受肺叶切除或亚肺叶切除(楔形切除或肺段切除)的临床IA期NSCLC患者,采用倾向性匹配与竞争风险模型比较5年OS和癌症复发风险。
- 共识别1687例临床IA期NSCLC患者,其中肺叶切除1354例、亚肺叶切除333例;倾向性匹配后得到325对。
- 次要指标包括收集的淋巴结数、病理升期和手术切缘状态。
主要发现
- 肺叶切除组与亚肺叶切除组5年OS相似(61.8% vs 55.6%,p=0.561)。
- 亚肺叶切除组NSCLC复发风险增加39%(风险比1.39;95%CI 1.04至1.87)。
- 肺叶切除组淋巴结数目中位数高于亚肺叶切除组(7枚[3,10] vs 1枚[0,4],p<0.001)。
关键数值与推荐
- 亚肺叶切除组复发风险:HR 1.39(95%CI 1.04–1.87)。
- 5年OS:肺叶切除组61.8% vs 亚肺叶切除组55.6%(p=0.561)。
- 淋巴结数目中位数:肺叶切除组7枚[3,10] vs 亚肺叶切除组1枚[0,4](p<0.001)。
临床怎么用
- 原文未据此给出推荐,作者指出在将现有比较这两种治疗的临床试验结果外推至临床使用时,必须考虑这些真实世界结果。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Lobectomy has been compared with sublobar resection for the treatment of stage IA non-small cell lung cancer (NSCLC). Accurate long-term data are lacking on the risk of recurrence in routine clinical practice. This study used a unique and representative dataset to compare recurrence, overall survival (OS), and lymph node staging between lobectomy and sublobar resection. METHODS: The American College of Surgeons performed a Special Study of the National Cancer Data Base, by reabstracting records to augment NSCLC data with enhanced information on preoperative comorbidity and cancer recurrence from 2007 to 2012. For patients treated with lobectomy or sublobar resection (wedge resection or segmentectomy) for clinical stage IA NSCLC, propensity matching and competing risks models compared 5-year OS and risk of cancer recurrence. Secondary measures included lymph nodes collected, pathologic upstaging, and surgical margin status. RESULTS: A total of 1,687 patients with stage IA NSCLC were identified (1,354 who underwent lobectomy, and 333 who had sublobar resections). Propensity matching yielded 325 pairs. Lobectomy and sublobar resection groups had similar 5-year OS (61.8% vs 55.6%, p = 0.561). The sublobar group had a 39% increased risk of NSCLC recurrence (hazard ratio, 1.39; 95% confidence interval, 1.04 to 1.87). Median lymph node counts were higher for lobectomy-treated patients (7 [3, 10] vs 1 [0, 4], p < 0.001)]. CONCLUSIONS: In an enhanced national dataset representative of outcomes for stage IA NSCLC, sublobar resection was associated with a 39% increased risk of cancer recurrence. The majority of patients treated with sublobar resection had an inadequate lymph node assessment. These real-world results must be considered when existing clinical trial results comparing these treatments are extrapolated for clinical use.
引用
- Subramanian M, McMurry T, Meyers BF, et al. Long-Term Results for Clinical Stage IA Lung Cancer: Comparing Lobectomy and Sublobar Resection. Ann Thorac Surg. 2018. PMID: 29580779. doi:10.1016/j.athoracsur.2018.02.049
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。